Genmab (GMAB)

Executive Summary

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of differentiated antibody therapeutics for oncology. With a robust pipeline of over 50 candidates, the company leverages its proprietary DuoBody® and HexaBody® platforms to create bispecific antibodies and other innovative biologics. Key commercial products include DARZALEX® (daratumumab) for multiple myeloma, developed in collaboration with Johnson & Johnson, and KESIMPTA® (ofatumumab) for multiple sclerosis, partnered with Novartis. Genmab's strategy focuses on advancing its clinical pipeline while generating revenue from existing partnerships and royalties. The company's lead wholly-owned asset, epcoritamab, a bispecific antibody targeting CD3 and CD20, is in Phase 2 trials for lymphoma and represents a significant near-term catalyst. Financially stable and with a strong track record, Genmab is well-positioned to deliver long-term value through its innovative pipeline and strategic collaborations.

Upcoming Catalysts (preview)

• H2 2026Epcoritamab Phase 2 data readout in relapsed/refractory follicular lymphoma or DLBCL70% success
• 2026Potential FDA label expansion for DARZALEX in smoldering multiple myeloma or frontline combination regimens80% success
• 2027Initiation of pivotal trials or early data for next-generation pipeline assets (e.g., GEN1057, HexaBody® programs)60% success